Erythropoietin (EPO) Market Report 2026

The erythropoietin (epo) market size has grown rapidly in recent years. It will grow from $19.25 billion in 2025 to $21.46 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to rising prevalence of anemia, increasing incidence of chronic kidney disease, established clinical effectiveness of epo therapy, advancements in recombinant biologic manufacturing, growing use of epo in cancer related anemia management.

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $35.04 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to expanding biosimilar approvals, increasing elderly population base, rising global dialysis patient volume, innovation in sustained release epo drugs, improving access to biologic therapies in emerging economies. Major trends in the forecast period include expanded use of erythropoietin in chronic kidney disease, rising adoption of biosimilar erythropoietin therapies, growing demand for long acting epo formulations, increasing use of epo in oncology supportive care, stricter regulatory oversight on epo safety and dosing.

The increasing prevalence of chronic kidney disease is expected to drive demand for the erythropoietin market in the coming years. A rise in chronic kidney disease cases necessitates the use of erythropoietin, which supports red blood cell production and helps improve immune function. For example, in 2023, according to the Centers for Disease Control, a US-based federal agency, around 14% of adults in the United States, representing approximately 35.5 million people, were estimated to be living with chronic kidney disease (CKD). As a result, the growing incidence of chronic kidney disease is contributing to higher demand for erythropoietin, thereby increasing market revenues.

The growing incidence of hematologic cancers is also anticipated to support the expansion of the erythropoietin market. Hematologic cancers are a group of malignancies that originate in the blood and affect the blood, bone marrow, or lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Erythropoietin plays an important role in the management of cancer-related anemia by stimulating red blood cell production, particularly in patients undergoing chemotherapy. For instance, in 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to cancer elimination, leukemia was estimated to affect 59,610 individuals in the United States and result in 23,710 deaths. In addition, non-Hodgkin lymphoma was projected to impact 80,550 new patients and cause 20,180 deaths. Therefore, the rising prevalence of hematologic cancers is further propelling growth in the erythropoietin market.

Major companies operating in the erythropoietin market are increasingly focused on introducing oral medications that provide more convenient alternatives to conventional injectable therapies. These innovations are intended to enhance patient comfort, adherence, and treatment flexibility, particularly for individuals managing chronic conditions such as anemia associated with chronic kidney disease. For example, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology company, introduced Jesduvroq (daprodustat) tablets. This oral therapy increases erythropoietin levels to help manage anemia in CKD patients by maintaining hemoglobin levels within a target range. The primary objective of Jesduvroq is to offer a more convenient option compared with injectable treatments, thereby improving comfort, compliance, and flexibility for patients, including those undergoing dialysis.

Major companies operating in the erythropoietin (epo) market are Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.

North America was the largest region in the erythropoietin (EPO) market in 2025. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in the erythropoietin (epo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the erythropoietin (epo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the erythropoietin market by increasing costs associated with imported active pharmaceutical ingredients and biologic production inputs. This has placed pricing pressure on both biologic and biosimilar epo products, particularly for renal disease and oncology applications. Regions with high dependence on cross border pharmaceutical supply chains such as asia pacific and europe are the most affected. At the same time, tariffs are encouraging local manufacturing expansion and regional supply chain strengthening, supporting long term market stability.

The erythropoietin (epo) market research report is one of a series of new reports that provides erythropoietin (epo) market statistics, including erythropoietin (epo) industry global market size, regional shares, competitors with a erythropoietin (epo) market share, detailed erythropoietin (epo) market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (epo) industry. This erythropoietin (epo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Erythropoietin (EPO) is a glycoprotein hormone that naturally stimulates the production of red blood cells and is produced by the peritubular cells of the kidneys. It is used to treat anemia, a condition characterized by a deficiency of red blood cells. Symptoms of anemia include weakness, fatigue, and shortness of breath, as red blood cells are responsible for transporting oxygen to tissues and organs.

The main product types in erythropoietin include epoetin alfa, epoetin beta, darbepoetin alfa, and others. Epoetin alfa is a recombinant DNA-derived form of human erythropoietin produced through cell culture techniques. The various drug classes include biologics and biosimilars, and these products are used in the treatment of cancer, hematological conditions, renal diseases, neurological disorders, and other applications.

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.